.. AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury AlloCure, Inc. Announced that it has initiated a phase 2 medical trial of AC607 today, the business’s mesenchymal stem cell therapy, as a potential treatment for severe kidney damage . The randomized, double-blind, placebo-controlled, multi-center trial, specified ACT-AKI , will enroll 200 cardiac surgery subjects at leading tertiary care centers in the United States. Brenner, M.D., AlloCure Chief and President Executive Officer. We have worked closely with leaders in the field on the design of ACT-AKI, and trial initiation signifies a significant milestone for AlloCure and the patients we collectively provide. AC607 is definitely a promising therapeutic candidate for AKI, that effective therapies are required greatly, stated Richard J.Treated mice had decreased lung bacterial burden and pass on also, compared to the control mice. Moreover, the treatment with nanoparticles happened once 24 hours every, a regimen that’s known to increase compliance in human patients, versus the usual dosing interval of inhaled antibiotics for P. Aeruginosa, which is twice daily. We were surprised and thrilled to see a 100 % survival advantage in mice treated daily with SCC22-loaded nanoparticles at doses considerably lower than those used to accomplish a similar survival benefit in twice-daily dosing of unencapsulated SCC22.